

Track record – Diseases – Infectious diseases

The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective. Setiawan D, Luttjeboer J, Westra TA, Wilschut JC, Suwantika AA, Daemen T, Atthobari J, Wilffert B, Postma MJ. *Expert Rev Vaccines*. 2014 Dec 6:1-16. [Epub ahead of print]

Cost-effectiveness of vaccination against herpes zoster. de Boer PT, Wilschut JC, Postma MJ. *Hum Vaccin Immunother*. 2014 Jul;10(7):2048-61. doi: 10.4161/hv.28670.

Economic evaluations of hepatitis A vaccination in middle-income countries. Suwantika AA, Yegenoglu S, Riewpaiboon A, Tu HA, Postma MJ. *Expert Rev Vaccines*. 2013 Dec;12(12):1479-94. doi: 10.1586/14760584.2013.851008. Epub 2013 Oct 30. Review.

Real-life persistence and adherence in ETV treated chronic hepatitis b patients: results of a German prospective multicenter observational study. Petersen J, Wilke T, Mauss S, Heyne R, Herold C, Wiese M, Boeker K, Pichl T, Hueppe D. *J Hepatol Suppl*. 2014;60(1):S423.

Sexually transmitted infections screening at HIV treatment centers for MSM can be cost-effective. Vriend HJ, Lugner AK, Xiridou M, Schim van der Loeff MF, Prins M, de Vries HJ, Geerlings SE, Prins JM, Rijnders BJ, van Veen MG, Fennema JS, Postma MJ, van der Sande MA. *AIDS*. 2013 Sep 10;27(14):2281-90. doi: 10.1097/QAD.0b013e32836281ee.

Modelling the impact of chlamydia screening on the transmission of HIV among men who have sex with men. Xiridou M, Vriend HJ, Lugner AK, Wallinga J, Fennema JS, Prins JM, Geerlings SE, Rijnders BJ, Prins M, de Vries HJ, Postma MJ, van Veen MG, Schim van der Loeff MF, van der Sande MA. *BMC Infect Dis*. 2013 Sep 18;13:436. doi: 10.1186/1471-2334-13-436.

Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review. Pechlivanoglou P, Le HH, Daenen S, Snowden JA, Postma MJ. *J Antimicrob Chemother*. 2014 Jan;69(1):1-11. doi: 10.1093/jac/dkt329. Epub 2013 Aug 23. Review.

Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective? Urbanus AT, van Keep M, Matser AA, Rozenbaum MH, Weegink CJ, van den Hoek A, Prins M, Postma MJ. *PLoS One*. 2013 Aug 12;8(8):e70319. doi: 10.1371/journal.pone.0070319. eCollection 2013.

The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. Rozenbaum MH, Pechlivanoglou P, van der Werf TS, Lo-Ten-Foe JR, Postma MJ, Hak E. *Eur J Clin Microbiol Infect Dis*. 2013 Mar;32(3):305-16. doi: 10.1007/s10096-012-1778-4. Epub 2012 Dec 14. Review.

Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands. Pierik JG, Gumbs PD, Fortanier SA, Van Steenwijk PC, Postma MJ. *BMC Infect Dis*. 2012 May 10;12:110. doi: 10.1186/1471-2334-12-110.

Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis. Postma MJ, Boersma C, Vandijck D, Vegter S, Le HH, Annemans L. *Expert Rev Pharmacoecon Outcomes Res*. 2011 Aug;11(4):367-9. doi: 10.1586/erp.11.50. No abstract available.

Cost-Effectiveness of Atazanavir/R Compared to Darunavir/R in Germany. Thuresson P, Verheggen B, Heeg B, Kaspar I, Erhardt W, Lescauwaet B. *PIN82 Value in Health* 01/2011; 14(7).

Modeling the Long Term Clinical Outcomes and Health Care Cost Impact of Initiating Treatment with Atazanavir/R Compared with Darunavir/R, Lopinavir/R and Efavirenz for HIV1 Infected Treatment-Naïve Patients: Country Results for Italy, Spain, Portugal and UK. Thuresson P. O., Verheggen B., Heeg B., Aldir I., Carrasco J., Didoni G., Mesa O. A., Lescauwaet B. *PIN73 Value in Health* 01/2011; 14(7)

Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden. Thuresson P, Heeg B, Lescauwaet B, Sennfält K, Alaeus A, Neubauer A. *Scandinavian Journal of Infectious Diseases* 01/2011; 43(4):304-1

Diagnostic accuracy of culture-based and PCR-based detection tests for methicillin-resistant Staphylococcus aureus: a meta-analysis. Luteijn JM, Hubben GA, Pechlivanoglou P, Bonten MJ, Postma MJ. *Clin Microbiol Infect*. 2011 Feb;17(2):146-54. doi: 10.1111/j.1469-0691.2010.03202.x.

Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the northern Netherlands between 2000 and 2006. Tu HA, Bos JH, Woerdenbag HJ, Visser ST, Wilschut JC, van Assen S, de Jong-van den Berg LT, Postma MJ. *Clin Ther.* 2010 Jan;32(1):133-44. doi: 10.1016/j.clinthera.2010.01.015.

Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening. Land JA, Van Bergen JE, Morr  SA, Postma MJ. *Hum Reprod Update.* 2010 Mar-Apr;16(2):189-204. doi: 10.1093/humupd/dmp035. Epub 2009 Oct 14. Review.

Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Logman JS, Stephens J, Heeg B, Haider S, Cappelleri J, Nathwani D, Tice A, van Hout B. *Current Medical Research and Opinion* 07/2010; 26(7):1565-78

Cost-effectiveness of atazanavir/r vs. Lopinavir/r in treatment naive hiv patients in Spain. Thuresson P, Heeg B, Serrano O, Ramirez de Arellano. *PIN56 Value in Health* 10/2009; 12(7)

Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs. Lugn r AK, Postma MJ. *Eur J Public Health.* 2009 Oct;19(5):516-20. doi: 10.1093/eurpub/ckp119. Epub 2009 Aug 19.

Economic evaluations of hepatitis B vaccination for developing countries. Tu HA, Woerdenbag HJ, Kane S, Riewpaiboon A, van Hulst M, Postma MJ. *Expert Rev Vaccines.* 2009 Jul;8(7):907-20. doi: 10.1586/erv.09.53. Review.

Excess drug prescriptions during influenza and RSV seasons in the Netherlands: potential implications for extended influenza vaccination. Assink MD, Kiewiet JP, Rozenbaum MH, Van den Berg PB, Hak E, Buskens EJ, Wilschut JC, Kroes AC, Postma MJ. *Vaccine.* 2009 Feb 11;27(7):1119-26. doi: 10.1016/j.vaccine.2008.11.070. Epub 2008 Dec 9.

Cost-effectiveness estimates for antenatal HIV testing in the Netherlands. Rozenbaum MH, Verweel G, Folkerts DK, Dronkers F, van den Hoek JA, Hartwig NG, de Groot R, Postma MJ. *Int J STD AIDS.* 2008 Oct;19(10):668-75. doi: 10.1258/ijisa.2008.008077.

Vancomycin vs teicoplanin in the treatment of Gram-positive infections: a pharmaco-economic analysis in a Turkish University Hospital. Sancar AA, Yegenoglu S, de Vries R, Postma MJ, Simsek N, Pechlivanoglou P, Unal S. *Pharm World Sci.* 2008 Dec;30(6):916-23. doi: 10.1007/s11096-008-9251-2. Epub 2008 Sep 21.

HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populations. Tramarin A, Gennaro N, Compostella FA, Gallo C, Wendelaar Bonga LJ, Postma MJ. *Curr Pharm Des.* 2008;14(17):1655-60.

Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Sander B, Nizam A, Garrison LP Jr, Postma MJ, Halloran ME, Longini IM Jr. *Value Health.* 2009 Mar-Apr;12(2):226-33. doi: 10.1111/j.1524-4733.2008.00437.x. Epub 2008 Jul 30.

Cost-effectiveness of HIV screening of blood donations in Accra (Ghana). van Hulst M, Sagoe KW, Vermande JE, van der Schaaf IP, van der Tuuk Adriani WP, Torpey K, Ansah J, Mingle JA, Smit Sibinga CT, Postma MJ. *Value Health.* 2008 Sep-Oct;11(5):809-19. doi: 10.1111/j.1524-4733.2008.00337.x. Epub 2008 May 16.

The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life. Hubben GA, Bishai D, Pechlivanoglou P, Cattelan AM, Grisetti R, Facchin C, Compostella FA, Bos JM, Postma MJ, Tramarin A. *AIDS Care.* 2008 Apr;20(4):449-55. doi: 10.1080/09540120701867107.

Cost-utility of repeated screening for Chlamydia trachomatis. de Vries R, van Bergen JE, de Jong-van den Berg LT, Postma MJ; PILOT-CT study group. *Value Health.* 2008 Mar-Apr;11(2):272-4. doi: 10.1111/j.1524-4733.2007.00225.x.

Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes. Postma MJ, Beardsworth P, Wilschut JC. *J Med Econ.* 2008;11(4):743-68. doi: 10.3111/13696990802505557. Review.

Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections. de Vries R, Daenen S, Tolley K, Glasmacher A, Prentice A, Howells S, Christopherson H, de Jong-van den Berg LT, Postma MJ. *Pharmacoeconomics.* 2008;26(1):75-90.

Health economic methodology illustrated with recent work on Chlamydia screening: the concept of extended dominance. Postma MJ, de Vries R, Welte R, Edmunds WJ. *Sex Transm Infect.* 2008 Apr;84(2):152-4. Epub 2007 Dec 12.

Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands. Hubben GA, Bos JM, Veltman-Starkenb CA, Stegmeijer S, Finnern HW, Kappelhoff BS, Simpson KN, Tramarin A, Postma MJ. *Cost Eff Resour Alloc.* 2007 Nov 22;5:15.

Cost-effectiveness analysis of caspofungin versus amphotericin b, voriconazole, and anidulafungin in the treatment of invasive candidiasis. Verheggen BG, Heeg BM, Vos C, Van Hout BA. *Value in Health*, Vol. 11, Issue 6, A437

Infectious disease economic evaluations in cost effectiveness analysis of reyataz[®] versus kaletra[®] in the treatment of naïve HIV patients in Italy. Neubauer AS, Van Hout BA, Thuresson PO, Intorcchia M, Heeg B. *IN1 Value in health* 2008

Inpatient and Outpatient Cost Model of Treating Gram+ Complicated Skin and Soft Tissue Infections (cSSTIs). Tice A, Heeg B, Nathwani D, Stephens J. *Infectious Diseases Society of America 2008 Annual Meeting*; 10/2008

A Bayesian meta-analysis of the efficacy of six antimicrobial agents for confirmed staphylococcus aureus complicated skin and soft-tissue infections (csstis). Logman J, Treur M, Verheggen B, Heeg B, Stephens J, Spiesser J, Simoneau D, Haider S. *PIN1 Value in health*, vol. 11, issue 6, A428. November, 2008

Cost effectiveness analysis of reyataz[®] versus kaletra[®] in the treatment of naïve HIV patients in Italy. Thuresson PO, Heeg B, Neubauer AS, Intorcchia M, Van Hout BA. *IN1 Value in Health* 01/2008; 11(6).

Assessing antimicrobial success rates in the treatment of methicillin-resistant staphylococcus aureus (mrsa) complicated skin and soft tissue infections (cssti): a bayesian meta-analysis. Logman J, Treur M, Verheggen B, Heeg B, Stephens J, Haider S, Cappelleri J, Nathwani D. *pin2 Value in Health*, Vol. 11, Issue 6, A428. November, 2008

Estimation and prediction of the HIV-AIDS-epidemic under conditions of HAART using mixtures of incubation time distributions. Heisterkamp SH, de Vries R, Sprenger HG, Hubben GA, Postma MJ. *Stat Med.* 2008 Mar 15;27(6):781-94.

Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands. Postma MJ, Novak A, Scheijbeler HW, Gyldmark M, van Genugten ML, Wilschut JC. *Pharmacoeconomics.* 2007;25(6):497-509.

Evaluation of the leukocyte esterase test (LET) as pre-screening test to reduce costs for national population-based Chlamydia trachomatis screening programs. Morr  SA, Spaargaren J, Veldhuijzen IK, Postma MJ, van Bergen JE, van Bergen JE, Broer J, Coenen AJ, G tz HM, de Groot F, Hoebe CJ, Richardus JH, van Schaik DT, Veldhuijzen IK, Verhooren M; PILOT CT study-group. *J Adolesc Health.* 2006 Apr;38(4):332-3; author reply 333-4. No abstract available.

Systematic screening for Chlamydia trachomatis: estimating cost-effectiveness using dynamic modeling and Dutch data. de Vries R, van Bergen JE, de Jong-van den Berg LT, Postma MJ; PILOT-CT Study Group. *Value Health.* 2006 Jan-Feb;9(1):1-11.

Economic evaluation of a randomized trial comparing Helicobacter pylori test-and-treat and prompt endoscopy strategies for managing dyspepsia in a primary-care setting. Klok RM, Arents NL, de Vries R, Thijs JC, Brouwers JR, Kleibeuker JH, Postma MJ. *Clin Ther.* 2005 Oct;27(10):1647-57.

Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults. Postma MJ, Jansema P, Scheijbeler HW, van Genugten ML. *Vaccine.* 2005 Nov 16;23(46-47):5365-71. Epub 2005 Jul 1.

Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases. Bos JM, Beutels P, Annemans L, Postma MJ. *Pharmacoeconomics.* 2004;22(18):1171-9. Review.

Effectiveness and cost-effectiveness of a pharmacy-based screening programme for Chlamydia trachomatis in a high-risk health centre population in Amsterdam using mailed home-collected urine samples. van Bergen JE, Postma MJ, Peerbooms PG, Spangenberg AC, Tjen-A-Tak J, Bindels PJ. *Int J STD AIDS.* 2004 Dec;15(12):797-802.

Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. Welte R, van den Dobbelen G, Bos JM, de Melker H, van Alphen L, Spanjaard L, R mke HC, Postma MJ. *Vaccine.* 2004 Dec 9;23(4):470-9.

Incremental cost-effectiveness of cyclooxygenase 2-selective versus nonselective nonsteroidal anti-inflammatory drugs in a cohort of coumarin users: a pharmacoeconomic analysis linked to a case-control study. Knijff-Dutmer EA, Postma MJ, van der Palen J, Brouwers JR, van de Laar MA. *Clin Ther.* 2004 Jul;26(7):1160-7.

Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam The Netherlands). Postma MJ, Bos JM, Beutels P, Schilthuis H, van den Hoek JA. *Vaccine*. 2004 May 7;22(15-16):1862-7.

Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy. Tramarin A, Parise N, Campostrini S, Yin DD, Postma MJ, Lyu R, Grisetti R, Capetti A, Cattelan AM, Di Toro MT, Mastroianni A, Pignattari E, Mondardini V, Calleri G, Raise E, Starace F; Palladio Study Group. *Qual Life Res*. 2004 Feb;13(1):243-50.

Cost-effectiveness of antenatal HIV-testing: reviewing its pharmaceutical and methodological aspects. Postma MJ, Sagoe KW, Dronkers F, Sprenger HG, de Jong- van den Berg L, Beck EJ. *Expert Opin Pharmacother*. 2004 Mar;5(3):521-8. Review.

A multicentre study of patient survival, disability, quality of life and cost of care: among patients with AIDS in northern Italy. Tramarin A, Campostrini S, Postma MJ, Calleri G, Tolley K, Parise N, de Lalla F; Palladio Study Group. *Pharmacoeconomics*. 2004;22(1):43-53.

A population based dynamic approach for estimating the cost effectiveness of screening for Chlamydia trachomatis. Welte R, Kretzschmar M, van den Hoek JA, Postma MJ. *Sex Transm Infect*. 2003 Oct;79(5):426. No abstract available.

[Dutch Institute for Health Care Improvement revised guideline, 'Sexually transmitted diseases and neonatal herpes']. Bleker OP, van der Meijden WI, Wittenberg J, van Bergen JE, Boeke AJ, van Doornum GJ, Henquet CJ, Galama JM, Postma MJ, Prins JM, van Voorst Vader PC; Centraal Begeleidingsorgaan voor de Intercollegiale Toetsing. *Ned Tijdschr Geneeskd*. 2003 Apr 12;147(15):695-9. Dutch.

The economic profile of antenatal HIV testing: pharmaceutical and methodological considerations. Postma MJ, Beck EJ, Sprenger HG, de Jong-van den Berg LT. *AIDS*. 2003 Mar 28;17(5):755-7. No abstract available.

Cost-effectiveness of widespread screening for Chlamydia trachomatis. Postma MJ, Welte R, Morr  SA. *Expert Opin Pharmacother*. 2002 Oct;3(10):1443-50. Review.

Routine HIV screening of sexually transmitted disease clinic attenders has favourable cost-effectiveness ratio in low HIV prevalence settings. Bos JM, van der Meijden WI, Swart W, Postma MJ. *AIDS*. 2002 May 24;16(8):1185-7.

HIV post-exposure prophylaxis: enhancing its pharmaco-economic profile by discriminate prescribing. Postma MJ, Bos JM, de Jong-van den Berg LT, Tramarin A, van Bergen JE. *AIDS*. 2002 May 24;16(8):1177-9. No abstract available.

Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence. Postma MJ, Jansema P, van Genugten ML, Heijnen ML, Jager JC, de Jong-van den Berg LT. *Drugs*. 2002;62(7):1013-24. Review.

Major improvements in cost effectiveness of screening women for Chlamydia trachomatis using pooled urine specimens and high performance testing. Morr  SA, Welte R, Postma MJ. *Sex Transm Infect*. 2002 Feb;78(1):74-5. No abstract available.

Comparing cost effectiveness of screening women for Chlamydia trachomatis in systematic and opportunistic approaches. Postma MJ, Welte R, van den Hoek JA, Morr  SA. *Sex Transm Infect*. 2002 Feb;78(1):73-4. No abstract available.

Cost-effectiveness of screening for genital Chlamydia trachomatis. Welte R, Jager H, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res*. 2001 Dec;1(2):145-56. doi: 10.1586/14737167.1.2.145.

Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia Trachomatis. Postma MJ, Welte R, van den Hoek JA, van Doornum GJ, Jager HC, Coutinho RA. *Value Health*. 2001 May-Jun;4(3):266-75.

The economics of HIV vaccines: projecting the impact of HIV vaccination of infants in sub-Saharan Africa. Bos JM, Postma MJ. *Pharmacoeconomics*. 2001;19(9):937-46. Review.

Cost-effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam. Bos JM, Fennema JS, Postma MJ. *AIDS*. 2001 Oct 19;15(15):2031-6.

Pharmacoeconomic evaluation of intensified antiretroviral treatment strategies in HIV/AIDS. Bos JM, Berg LT, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res*. 2001 Oct;1(1):77-84. doi: 10.1586/14737167.1.1.77.

Pharmacoeconomics of Helicobacter pylori: eradication versus maintenance therapy in controlling peptic ulcer disease.

Klok RM, Brouwers JR, Postma MJ. Expert Rev Pharmacoecon Outcomes Res. 2001 Oct;1(1):19-24. doi: 10.1586/14737167.1.1.19.

Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program. Bos JM, Rümke HC, Welte R, Postma MJ, Jager JC. Vaccine. 2001 Oct 12;20(1-2):202-7.

Cost effectiveness analysis of a population based screening program for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens. van Valkengoed IG, Postma MJ, Morré SA, van den Brule AJ, Meijer CJ, Bouter LM, Boeke AJ. Sex Transm Infect. 2001 Aug;77(4):276-82.

Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands. Postma MJ, Heijnen ML, Jager JC. Pharmacoeconomics. 2001;19(2):215-22.

Socio-economic aspects of extended STD screening in pregnancy. Postma MJ, Jager JC, de Jong-van den Berg LT. AIDS Care. 2000 Dec;12(6):731-5.

Comparative model-based analysis of screening programs for Chlamydia trachomatis infections. Kretzschmar M, Welte R, van den Hoek A, Postma MJ. Am J Epidemiol. 2001 Jan 1;153(1):90-101.

[Screening for asymptomatic Chlamydia trachomatis Infection in pregnancy; cost-effectiveness favorable at a minimum prevalence rate of 3% or more]. Postma MJ, Bakker A, Welte R, van Bergen JE, van den Hoek JA, de Jong-van den Berg LT, Jager JC. Ned Tijdschr Geneesk. 2000 Dec 2;144(49):2350-4. Dutch.

Cost effectiveness of expanded antenatal HIV testing in London. Postma MJ, Beck EJ, Hankins CA, Mandalia S, Jager JC, de Jong-van den Berg LT, Walters MD, Sherr L. AIDS. 2000 Oct 20;14(15):2383-9.

Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence. Postma MJ, Baltussen RM, Heijnen ML, de Berg LT, Jager JC. Drugs Aging. 2000 Sep;17(3):217-27. Review.

Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach. Welte R, Kretzschmar M, Leidl R, van den Hoek A, Jager JC, Postma MJ. Sex Transm Dis. 2000 Oct;27(9):518-29.

Hospital care for persons with AIDS in European-Union countries; a cross-country comparison. Postma MJ, Kornarou H, Pappazios V, Leidl RM, Tolley K, Kyriopoulos J, Jager JC. Health Care Manag Sci. 2000 Jan;3(1):1-7.

[Pharmaco-economic evaluation of mandatory HIV-screening in pregnancy; a cost-efficacy analysis in Amsterdam]. Postma MJ, van den Hoek JA, Beck EJ, Heeg B, Jager JC, Coutinho RA. Ned Tijdschr Geneesk. 2000 Apr 15;144(16):749-54. Dutch.

[Pharmaco-economic evaluation of mandatory HIV-screening in pregnancy; a cost-efficacy analysis in Amsterdam]. Postma M, van den Hoek J, Beck J, Heeg B, Jager J, Coutinho R. Nederlands tijdschrift voor geneeskunde 05/2000; 144(16):749-54.

Economic evaluation of influenza vaccination. Assessment for The Netherlands. Postma MJ, Bos JM, van Gennep M, Jager JC, Baltussen R, Sprenger MJ. Pharmacoeconomics. 1999;16 Suppl 1:33-40. Review.

[Opportunistic screening for genital infections with Chlamydia trachomatis among the sexually active population in Amsterdam. III. Cost-effectiveness analysis of screening women and the role of reinfection and partner treatment]. Postma MJ, Welte R, van den Hoek JA, Jager JC, van Doornum GJ, Coutinho RA. Ned Tijdschr Geneesk. 1999 Nov 20;143(47):2383-5. Dutch.

[Screening for Chlamydia trachomatis infection: which target group and at what price?]. Postma MJ, van den Hoek JA. Ned Tijdschr Geneesk. 1999 Jun 5;143(23):1237-8. Dutch. No abstract available.

Universal HIV screening of pregnant women in England: cost effectiveness analysis. Postma MJ, Beck EJ, Mandalia S, Sherr L, Walters MD, Houweling H, Jager JC. BMJ. 1999 Jun 19;318(7199):1656-60.

[Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women]. Postma MJ, Welte R, van den Hoek JA, van Doornum GJ, Coutinho RA, Jager JC. Ned Tijdschr Geneesk. 1999 Mar 27;143(13):677-81. Dutch.

Estimating influenza-related hospitalization in The Netherlands. Baltussen RM, Reinders A, Sprenger MJ, Postma MJ, Jager JC, Ament AJ, Leidl RM. *Epidemiol Infect.* 1998 Aug;121(1):129-38.

Disease-staging for modelling current and future health-care impact of disease: illustrations for diabetes mellitus and AIDS. Postma MJ, Jager JC, Ruwaard D, van Loy NC, Leidl RM. *Health Policy.* 1998 Jan;43(1):45-54.

Hospital care for persons with AIDS in the European Union. Postma MJ, Tolley K, Leidl RM, Downs AM, Beck EJ, Tramarin AM, Flori YA, Santin M, Antofianzas F, Kornarou H, Pappas VC, Dijkgraaf MG, Borleffs J, Luijben AJ, Jager JC. *Health Policy.* 1997 Aug;41(2):157-76.

[Cost-effectiveness of influenza vaccination The Netherlands]. Reinders A, Postma MJ, Govaert TM, Sprenger MJ. *Ned Tijdschr Geneesk.* 1997 Jan 11;141(2):93-7. Dutch.

Comparative impact assessment of AIDS: between doomsday and complacency. Jager JC, Achterberg PW, Postma MJ, Houweling H. *AIDS.* 1996 Feb;10(2):238-40. No abstract available.

Lifetime hospitalization profiles for symptomatic, HIV-infected persons. Dijkgraaf MG, Luijben AH, Postma MJ, Borleffs JC, Schrijvers AJ, Jager JC. *Health Policy.* 1996 Jan;35(1):13-32. Review.

AIDS scenarios for The Netherlands; the economic impact on hospitals. Postma MJ, Jager JC, Dijkgraaf MG, Borleffs JC, Tolley K, Leidl RM. *Health Policy.* 1995 Feb;31(2):127-50.

Economic impact of the AIDS epidemic in the European Community: towards multinational scenarios on hospital care and costs. Postma MJ, Leidl R, Downs AM, Rovira J, Tolley K, Gyldmark M, Jager JC. *AIDS.* 1993 Apr;7(4):541-53. Review.

[Benefit of the serological screening program for syphilis in pregnant women in Amsterdam in the period 1985-1989]. Bindels PJ, Postma MJ, Peerbooms PG, Coutinho RA, van den Hoek JA. *Ned Tijdschr Geneesk.* 1991 Jul 20;135(29):1319-22. Dutch.

AIDS impact scenarios: questions for the years to come. Jager HC, Postma MJ, Leidl R, Majnoni d'Intignano B, Baert AE. *AIDS.* 1990 Nov;4(11):1166-7. No abstract available.